Tarlatamab Maintains Efficacy and Safety with Extended Dosing in Small Cell Lung Cancer

A randomized Phase II study (DeLLphi‑309) presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC) evaluated extended‑interval dosing regimens of tarlatamab in patients with previously treated small cell lung cancer (SCLC). The trial compared the standard every‑two‑week schedule with longer dosing intervals and found that the extended regimens maintained comparable efficacy, safety, and pharmacokinetic profiles to the established schedule.

Patients receiving the extended‑interval dosing demonstrated similar objective response rates, progression‑free survival, and overall survival to those on the every‑two‑week regimen. Adverse event rates and severity were also comparable across groups, indicating that the drug’s safety profile is preserved when dosing intervals are lengthened. Pharmacokinetic analyses confirmed that trough concentrations and exposure levels remained within therapeutic ranges, supporting the feasibility of less frequent dosing.

These findings suggest that tarlatamab can be administered with extended intervals without compromising clinical benefit or increasing toxicity in SCLC patients who have received prior therapy. The results may offer greater flexibility in treatment planning and improve patient convenience while maintaining the drug’s therapeutic effectiveness.